Biomarkers, Pharmacological
"Biomarkers, Pharmacological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Measurable biological parameters that serve for drug development, safety and dosing (DRUG MONITORING).
| Descriptor ID |
D054316
|
| MeSH Number(s) |
D23.101.137
|
| Concept/Terms |
Biomarkers, Pharmacological- Biomarkers, Pharmacological
- Pharmacological Biomarkers
- Biological Markers, Pharmacological
- Markers, Pharmacological Biological
- Pharmacological Biological Markers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Pharmacological".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Pharmacological".
This graph shows the total number of publications written about "Biomarkers, Pharmacological" by people in this website by year, and whether "Biomarkers, Pharmacological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Pharmacological" by people in Profiles.
-
Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial. Pediatr Diabetes. 2019 11; 20(7):871-879.
-
Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):379-386.
-
Treatment response prediction and individualized identification of first-episode drug-na?ve schizophrenia using brain functional connectivity. Mol Psychiatry. 2020 04; 25(4):906-913.
-
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. PLoS One. 2017; 12(2):e0171753.
-
Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res. 2013 Sep 01; 19(17):4889-99.
-
Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.
-
Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle. 2013 Feb 15; 12(4):647-54.
-
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab. 2012 Nov; 107(3):308-14.
-
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012 Jan; 35(1):66-72.
-
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03; 118(18):4985-91.